GSK’s 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, is currently under review in the United States. A decision from the FDA is expected on Feb. 14, 2025.

GSK has received the Food and Drug Administration’s permission for Penmenvy (meningococcal groups A, B, C, W and Y vaccine) for use in individuals aged 10 through 25 years.

The vaccine combines the antigenic components of GSK’s two well-established meningococcal vaccines, BEXSERO (Meningococcal Group B Vaccine) and MENVEO (Meningococcal [Groups A, C, Y, and W-135 ...

GSK’s MenABCWY vaccine combines the antigenic components of the Company’s two well-established meningococcal vaccines—BEXSERO (Meningococcal Group B Vaccine) and MENVEO (Meningococcal ...

Importantly, Penmenvy integrates the antigenic components of GSK’s two widely used meningococcal vaccines, Bexsero (Meningococcal Group B Vaccine) and Menveo (Meningococcal [Groups A, C, Y, and ...

GSK said its five-in-one meningococcal vaccine Penmenvy was approved by the U.S. Food and Drug Administration. The British pharmaceutical company on Monday said the vaccine was authorized for use ...

GSK's 5-In-1 Meningococcal Vaccine Gets Positive Recommendation From U.S. Advisory Committee on Immunization Practices Published: April 17, 2025, 2:28 a.m. ET Share Resize ...

The U.S. Food and Drug Administration approved a GSK meningococcal vaccine for people aged 10 to 25, which will be one of its major product launches this year and rival a first-to-market shot from ...

GSK’s 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices Business Wire Apr 16, 2025 ...